Imagine a world where we can finally cure, not just treat, one of the most devastating childhood cancers. Ependymomas, the third most common brain tumor in children, have long resisted our best efforts, leaving families with only temporary solutions. But a groundbreaking study from the University of Michigan, published in Nature, has uncovered a surprising new target: a molecule called itaconate. This discovery could revolutionize how we fight these tumors.
Ependymomas are relentless, affecting approximately 250 children in the United States annually, with most diagnoses occurring in children eight and younger. Despite decades of research, current treatments only extend survival—they don’t eradicate the disease. But here’s where it gets controversial: researchers have found that itaconate, a metabolite typically produced by immune cells to fight infections, is also manufactured by these brain tumors. Why would a brain tumor hijack a process meant for immune defense? And this is the part most people miss—itaconate isn’t just a bystander; it actively fuels tumor growth.
In their study, the team discovered that over 80% of ependymomas in the upper brain contain a cancer-causing protein fusion called ZFTA-RELA. Individually, ZFTA and RELA are harmless, but when fused, they become a deadly duo driving tumor development. The researchers dug deeper into the metabolic changes that enable this growth and found that ependymomas produce itaconate through an enzyme called ACOD1. When they blocked ACOD1 in mouse models, tumor growth slowed significantly.
Here’s the fascinating twist: itaconate forms a feedback loop with ZFTA-RELA, where each boosts the other’s activity, creating a vicious cycle of tumor growth. This loop depends on the amino acid glutamine, which acts as a building block for itaconate synthesis. By disrupting this loop, researchers reduced ZFTA-RELA levels and shrank tumors in mice. This raises a bold question: Could targeting itaconate be the key to finally curing ependymomas?
Lead researcher Sriram Venneti, M.D., Ph.D., emphasizes the significance of this finding: 'This is the first study to show that the ZFTA-RELA fusion can be targeted in this type of tumor.' The team is now working with the Pediatric Neuro-Oncology Consortium to develop a clinical trial targeting the itaconate pathway in patients. They’re also exploring whether similar protein fusions in other cancers could be tackled using this approach.
But here’s the controversial part: If itaconate is so critical to tumor growth, why hasn’t it been targeted before? And could this discovery lead to unintended consequences, given its role in immune function? These questions spark debate and highlight the complexity of cancer biology. What do you think? Is this the breakthrough we’ve been waiting for, or are there hidden risks we need to consider?
This research was funded by multiple organizations, including the Sontag Foundation, Doris Duke Charitable Foundation, and the Hyundai Hope On Wheels Foundation, among others. The full study, 'ZFTA-RELA ependymomas produce itaconate to epigenetically sustain pathogenic fusion expression,' is available in Nature (DOI: 10.1038/s41586-025-10005-1).
Let’s keep the conversation going. What are your thoughts on this groundbreaking discovery? Could itaconate be the game-changer for pediatric brain cancer treatment? Share your opinions in the comments below!
